CombiMatrix's Q1 Revenues Jump 27 Percent on Prenatal Microarray Testing Demand

May 08, 2013

|

NEW YORK (GenomeWeb News) – CombiMatrix today announced a 27 percent rise in first-quarter revenues, driven by a 158 percent jump in sales generated by its prenatal chromosomal microarray analysis testing services.

The Irvine, Calif.-based molecular diagnostics company said that total revenues for the three months ended March 31 increased to $1.6 million from $1.2 million in the first quarter of 2012. Growth in prenatal testing revenues was driven by a 124 percent increase in billable test volumes, as the firm noted when it released its preliminary results one month ago.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

To Control the Spread

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

More to Do

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

This Week in PLOS

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

'Follow Me to Maryland'

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.

Featured White Papers

FFPE controls for use with Ion AmpliSeq and Oncomine ALK, RET, and ROS1 fusion assays

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Oct

17

Featured Webinar

Reliable RNA-Seq Expression Profiling from Low-Quality FFPE Biobank Samples

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu